MTDMEDIUM SIGNALFINANCIAL10-K

MTD's stockholders' equity improved significantly from deeply negative territory while the company expanded operations through debt-funded growth.

The dramatic 81% improvement in stockholders' equity from -$127M to -$24M suggests MTD is making meaningful progress toward financial stability, though it remains in negative equity territory. The company appears to be investing in growth with increased assets, receivables, and inventory, but this expansion is primarily debt-financed as total debt increased 14% to $2.1B.

Comparing 2026-02-06 vs 2025-02-07View on EDGAR →
FINANCIAL ANALYSIS

MTD demonstrated mixed financial performance with substantial improvement in stockholders' equity moving closer to positive territory, while total assets grew 14.6% to $3.7B driven by increases in receivables (+13.3%) and inventory (+13.1%) suggesting business expansion. However, this growth was debt-financed with total debt rising 14% to $2.1B and cash declining 27% to $70M, indicating the company is leveraging up to fund operations and growth. The overall picture shows a company in recovery mode with improving equity position but increasing financial leverage and declining liquidity.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+81.4%
-$126.9M-$23.6M

Equity base grew 81.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
-27.3%
$96.0M$69.8M

Cash decreased 27.3% — monitor burn rate and upcoming capital needs.

Total Assets
Balance Sheet
+14.6%
$3.2B$3.7B

Asset base grew 14.6% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+14.1%
$1.2B$1.4B

Current assets grew 14.1% — improving short-term liquidity or inventory/receivables build.

Total Debt
Balance Sheet
+14%
$1.8B$2.1B

Debt rose 14% — additional borrowing for investment or operations; monitor coverage ratios.

Accounts Receivable
Balance Sheet
+13.3%
$687.1M$778.2M

Receivables grew 13.3% — monitor days sales outstanding for collection efficiency.

Inventory
Balance Sheet
+13.1%
$342.3M$387.2M

Inventory built 13.1% — monitor whether demand supports this build or if write-downs may follow.

Total Liabilities
Balance Sheet
+11%
$3.4B$3.7B

Liabilities increased 11% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-02-06
PRIOR — 2025-02-07
ADDED
The aggregate market value of the shares of Common Stock held by non-affiliates of the registrant on June 30, 2025 (based on the closing price for the Common Stock on the New York Stock Exchange as of the last business day of the registrant s most recently completed second fiscal quarter, June 30, 2025) was approximately $ 24.2 billion.
Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties.
Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements, including ongoing developments related to global trade disputes/tariffs, governmental policies, the geopolitical environment, inflation, the conflict in Ukraine and continuing instability in the Middle East.
Our business is geographically diversified, with net sales in 2025 derived 42% from North and South America, 29% from Europe, and 29% from Asia and other countries.
The laboratory instruments and related service business accounted for approximately 56% of our net sales in 2025 and 2024, compared to 55% in 2023.
+7 more — sign up free →
REMOVED
The aggregate market value of the shares of Common Stock held by non-affiliates of the registrant on June 28, 2024 (based on the closing price for the Common Stock on the New York Stock Exchange as of the last business day of the registrant s most recently completed second fiscal quarter, June 28, 2024) was approximately $ 29.7 billion.
Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties, including statements about expected revenue growth, inflation, ongoing developments related to Ukraine, and the conflict in the Middle East.
Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements, including inflation, ongoing developments related to Ukraine, and the conflict in the Middle East.
Our business is geographically diversified, with net sales in 2024 derived 42% from North and South America, 28% from Europe, and 30% from Asia and other countries.
The laboratory instruments and related service business accounted for approximately 56% of our net sales in 2024, 55% in 2023, and 57% in 2022.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →